BW
OBIO icon

Boaz Weinstein’s Orchestra BioMed OBIO Stock Holding History

Boaz Weinstein’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-737,488
Closed -$7.34M – 1143
2022
Q2 		$7.34M Hold
737,488
– – 0.09% 431
2022
Q1 		$7.31M Buy
+737,488
New +$7.28M 0.1% 342

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Boaz Weinstein's OBIO Position: Q3 2022 in Review

Boaz Weinstein sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 737,488 shares — an estimated $7.34M sold.

Boaz Weinstein first reported a position in OBIO in Q1 2022 and held it in 2 quarters. The position peaked at $7.34M in Q2 2022. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

  • Boaz Weinstein reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
  • Boaz Weinstein sold 737,488 Orchestra BioMed shares in Q3 2022, an estimated $7.34M.
  • Boaz Weinstein first reported a position in Orchestra BioMed in Q1 2022 and held it in 2 quarters.
  • Boaz Weinstein's Orchestra BioMed position peaked at $7.34M in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Saba Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.